We use cookies to improve our service and to tailor our content and advertising to you. More infoClose You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policyClose
Clinical trial regulations should remove unnecessary obstacles for the conduct of pragmatic trials assessing the comparative effectiveness of medicines posing no or minimal risk to participants, say Rafael Dal-Ré and colleagues
